University of Pittsburgh
400 Craig Hall
200 Forbes Pavilion
Tel: 412-624-4147 or 412-624-0409
280 articles with University of Pittsburgh
Coeptis Therapeutics Enters into Sponsored Research Agreement with the University of Pittsburgh to Advance SNAP-CAR Development Program
Coeptis Therapeutics Holdings, Inc. today announced a sponsored research agreement with the University of Pittsburgh to advance pre-clinical development of SNAP-CAR T cells targeting HER2 as well as identify opportunities to expand the applicability of SNAP-CAR in oncology.
Genprex Signs Exclusive License to Additional Diabetes Technology with the University of Pittsburgh
Genprex, Inc. announced it has entered into an exclusive license agreement with the University of Pittsburgh, granting Genprex a worldwide, exclusive license to a patent application and related technology and a worldwide, non-exclusive license to use certain related know-how, all related to gene therapy for Type 2 diabetes using the genes of the Pdx1 and MafA transcription factors.
Genprex Strengthens Diabetes Gene Therapy Program with License of Additional Technology from University of Pittsburgh
Genprex, Inc. today announced it has entered into an exclusive license agreement (the Agreement) with the University of Pittsburgh, granting Genprex a worldwide, exclusive license to certain patent applications and related technology and a worldwide, non-exclusive license to use certain related know-how, all related to modulating autoimmunity in Type 1 diabetes by using gene therapy.
Synchron to Begin Patient Enrollment for the COMMAND Trial of a Brain Computer Interface at University of Pittsburgh
Synchron announced enrollment in the COMMAND trial has commenced at the University of Pittsburgh, Pittsburgh, PA.
Coeptis Therapeutics Enters Exclusive License Agreement with University of Pittsburgh for Rights to SNAP-CAR
Coeptis Therapeutics, Inc. today announced entry into an exclusive license agreement with the University of Pittsburgh for the rights to a chimeric antigen receptor T cell (CAR T) technology – SNAP-CAR – designed to target multiple antigens simultaneously and potentially address a range of hematologic and solid tumors, including breast and ovarian cancer.
Covid-19, aging, stroke, ALS, colorectal cancers and Alzheimer's disease are all the focus of this week's top research stories.
Key findings identify the mechanism behind how senescent cells become zombified, migraine drugs could combat obesity and new AI may identify vaccine hesitancy.
Coeptis Therapeutics Enters into Exclusive Option Agreement with University of Pittsburgh for Rights to CAR-T Technologies Designed to Target Multiple Cancer Indications, Including Hematologic and Solid Tumors
Coeptis Therapeutics, Inc. today announced entry into an exclusive option agreement with the University of Pittsburgh for the rights to three chimeric antigen receptor T cell (CAR-T) technologies that offer the potential to address a range of hematologic and solid tumors.
The Richard King Mellon Foundation has awarded a $100 million gift to the University of Pittsburgh and approved a $150 million grant for Carnegie Mellon University.
BridgeBio Pharma Announces Collaborations with Three Academic Research Institutions
BridgeBio Pharma, Inc. today announced three new academic collaborations with MUSC Foundation for Research Development, Stanford University and the University of Pittsburgh (Pitt) to translate cutting-edge discoveries into potential therapies for patients with genetic diseases and genetically driven cancers.
Kezar Life Sciences Announces Formation of Clinical Advisory Committee
Kezar Life Sciences, Inc., a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, announced the formation of its Clinical Advisory Committee.
Pitt's Plans for Growth of Regional Life Sciences Cluster Get Boost From $25 Million Gift; Advancements in Vision Care Lead the Way
Philadelphia has its pharmaceutical cluster, San Francisco is known for its tech startups, and Boston boasts about its investment capital.
Clinical Catch-Up: September 7-11
9/14/2020It was a busy week for clinical trial updates. Here’s a look.
It’s likely that more companies and universities will add additional assets as time goes on.
Almost 15,000 physicians, scientists, health care professionals and industry representatives from around the globe presented research, treatment recommendations and advances toward a diabetes cure at the American Diabetes Association's 79th Scientific Sessions in San Francisco this week.
Verily announced a strategic collaboration deal with Novartis, Otsuka, Pfizer, Sanofi and six major health systems.
A bacteriophage is a virus that infects bacteria. They aren’t typically used to treat bacterial infections, but in desperate cases, they have been used to treat particularly antibiotic-resistant infections.
Today has been marked by a wide range of life science and biopharma stories. Here’s a broader look at some of the top stories.
Research Roundup: Gene Therapy for Deafness, Autism Genes, Breakthroughs in Parkinson’s and ALS, ...
3/1/2019There are plenty of great scientific research stories out this week. Here’s a look at just a few of them.
The U.S. Senate Finance Committee and the House Oversight Committee started hearings on Tuesday, January 29, focused on dealing with high drug prices.